Swiss Construction Stock News

SWX:ROP
SWX:ROPPharmaceuticals

Roche Diagnostics Launches New Assays As Investors Weigh Valuation Gap

Roche Holding (SWX:ROP) has received CE marking for its cobas MPX-E assay, enabling simultaneous screening for HIV, hepatitis C, B, and E in blood donations. The company has also launched the cobas eplex RP3 respiratory panel, designed to test for up to 25 respiratory pathogens in a single rapid assay. These diagnostics products target blood safety, laboratory efficiency, and faster respiratory infection diagnosis across clinical settings. Roche Holding, trading at around CHF318.0,...
SWX:AMRZ
SWX:AMRZBasic Materials

Amrize Expands West Texas Footprint With PB Materials Acquisition

Amrize (SWX:AMRZ) has completed the acquisition of PB Materials Holdings, adding 26 locations across West Texas. The move increases Amrize’s presence in a region with significant infrastructure and energy related project activity. The transaction reflects Amrize’s push to grow business lines that are less tied to the residential construction cycle. Amrize, listed as SWX:AMRZ, now trades at CHF43.64 per share, with the stock showing a 0.8% decline over the past week and a 1.9% decline year...
SWX:PGHN
SWX:PGHNCapital Markets

Partners Group Weighs Healthcare Expansion And Tech Deal To Reshape Growth

Partners Group Holding (SWX:PGHN) has appointed Pete Zippelius as Co-Head of its Private Equity Health & Life vertical, sharpening its focus on healthcare and life sciences. The firm is also reported to be in early discussions to acquire a significant stake in Happiest Minds Technologies alongside other private equity investors. Partners Group Holding, trading at around CHF866.0, has seen mixed share performance, with a 4.2% gain over the past week and 5.6% over the past month, set against...
SWX:SOON
SWX:SOONMedical Equipment

Does Selling Its Sennheiser Consumer Unit Refocus Sonova (SWX:SOON) On Higher‑Value Hearing Care?

In March 2026, Sonova Holding AG announced plans to sell its Consumer Hearing business, which markets premium audio products under the Sennheiser brand, and said it will classify this unit as discontinued operations in its 2026 financial results. The move highlights a sharpened focus on Sonova’s core innovation areas in hearing care, while it simultaneously explores geo-targeted retail acquisitions to reshape its portfolio. Next, we’ll examine how exiting the Sennheiser-branded Consumer...
SWX:PGHN
SWX:PGHNCapital Markets

A Look At Partners Group Holding (SWX:PGHN) Valuation After Recent Share Price Momentum

Recent performance snapshot Partners Group Holding (SWX:PGHN) has drawn attention after a recent share price move, with the stock up 2.6% over the past day and 4.6% over the past week on the Swiss market. See our latest analysis for Partners Group Holding. That short term momentum contrasts with a 90 day share price return of an 11.62% decline and a 1 year total shareholder return showing a 27.63% loss, while the 3 year total shareholder return of 16.27% points to a stronger longer run...
SWX:BAER
SWX:BAERCapital Markets

Is Julius Bär’s Call of its US$350m AT1 Bond Quietly Reframing the Case for (SWX:BAER)?

In March 2026, Julius Bär Gruppe AG announced it would exercise its option to redeem all outstanding Perpetual Tier 1 Subordinated Bonds (ISIN: XS2238020445), originally issued on 8 October 2020 with a 4.875% coupon and an aggregate nominal amount of US$350,000,000, at par plus accrued interest on the first call date of 8 April 2026. This early redemption under condition 3(c) highlights Julius Bär’s active approach to capital structure management, reflecting how it balances funding costs,...
SWX:LONN
SWX:LONNLife Sciences

Lonza Group (SWX:LONN) Is Up 5.8% After 25% Dividend Hike And Board Refresh - Has The Bull Case Changed?

Lonza recently published its 2025 Annual and Sustainability Reports, called its 2026 Annual General Meeting for 8 May in Basel, and proposed a 25% dividend increase alongside a broad board refresh. The nomination of former Eli Lilly executive Stephen Fry and other new directors with healthcare, automation, AI and biopharma expertise underscores Lonza’s emphasis on governance quality and future-focused capabilities in its core CDMO business. We’ll now explore how Lonza’s planned 25% dividend...
SWX:EMMN
SWX:EMMNFood

Emmi’s Exit From FTSE All‑World Index Might Change The Case For Investing In Emmi (SWX:EMMN)

In March 2026, Emmi AG was removed from the FTSE All-World Index, altering its representation in a widely followed global equity benchmark. This index removal may influence how index-tracking institutional investors allocate capital to Emmi, potentially reshaping its visibility in global portfolios. Next, we will examine how Emmi's removal from the FTSE All-World Index may influence its investment narrative and investor perception. Capitalize on the AI infrastructure supercycle with our...
SWX:SWON
SWX:SWONElectronic

SoftwareOne Holding (SWX:SWON) Returns To Profit But Thin Margins Test Bullish Narratives

SoftwareOne Holding (SWX:SWON) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 486.6 million and basic EPS of CHF 0.07, while the trailing twelve months show revenue of CHF 1.2 billion and basic EPS of CHF 0.13. Over the past reported periods, revenue has moved from CHF 529.2 million and EPS of CHF 0.18 in the first half of 2024 to CHF 486.2 million and an EPS loss of CHF 0.19 in the second half of 2024, before landing at the latest CHF 486.6 million and CHF...
SWX:SQN
SWX:SQNCapital Markets

Does Swissquote’s 2025 Profit Jump And Higher Dividend Change The Bull Case For SWX:SQN?

Swissquote Group Holding SA has released its full-year 2025 results, reporting net income of CHF 366.39 million and basic earnings per share from continuing operations of CHF 24.49, alongside declaring an annual dividend of CHF 7.40 per share payable in May 2026. The combination of higher earnings and a larger cash payout suggests management is comfortable sharing more of the company’s profitability with shareholders. We’ll now explore how Swissquote’s strong 2025 earnings and increased CHF...
SWX:IDIA
SWX:IDIABiotechs

A Look At Idorsia’s Valuation After Positive Pediatric Insomnia Phase 2 Results

Why Idorsia’s latest pediatric insomnia data matters for shareholders Idorsia (SWX:IDIA) shares have moved after the company reported positive top-line Phase 2 results for daridorexant in children with insomnia disorder, including patients with neurodevelopmental conditions, and outlined plans to engage regulators on next steps. The trial used a 2 week treatment period and showed a statistically significant, dose-dependent improvement in total sleep time from baseline on Day 1, along with...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis Targets Chronic Disease Growth With Excellergy Deal And Fabhalta Data

Novartis (SWX:NOVN) agreed to acquire Excellergy, a biotech focused on anti IgE therapies for allergic diseases, including food allergies. The company reported positive final two year Phase III results for Fabhalta in IgA nephropathy, indicating slower kidney function decline in the study population. The FDA granted Fabhalta priority review for traditional approval in IgA nephropathy. For investors watching large pharma, Novartis sits at the intersection of immunology, allergy, and kidney...
SWX:PPGN
SWX:PPGNLife Sciences

A Look At PolyPeptide Group’s Valuation As It Expands Its €200 Million Credit Facility

PolyPeptide Group (SWX:PPGN) has expanded its credit facility to €200 million, bringing ING Bank into its lending group alongside UBS, Danske Bank and Zürcher Kantonalbank to support its revenue and capacity expansion objectives. See our latest analysis for PolyPeptide Group. That credit facility news arrives as momentum has been picking up, with the 7 day share price return of 8.54% and year to date share price return of 11.25% feeding into a 1 year total shareholder return of 62.61%. The...
SWX:NESN
SWX:NESNFood

Is Nestlé (SWX:NESN) Offering Value After Recent Share Price Weakness?

Wondering whether Nestlé at around CHF 76.37 is priced for quality, or leaving some value on the table for patient shareholders? The stock is up 0.7% over the last week, while the 30 day return is a 9.1% decline and the one year return is a 12.3% decline, which may change how you think about both upside and risk. Recent coverage has focused on Nestlé's position as a global consumer staples giant, its broad portfolio of food and beverage brands, and how that scale influences investor...
SWX:SDZ
SWX:SDZPharmaceuticals

Assessing Sandoz Group (SWX:SDZ) Valuation After Strong One Year Shareholder Returns

Recent share performance snapshot Sandoz Group (SWX:SDZ) has seen a mix of short term pressure and longer term strength, with a 0.3% decline over the past day, 0.5% over the past week and 16.5% over the past month, but a 3.2% gain over the past 3 months and a 62.6% total return over the past year. See our latest analysis for Sandoz Group. The recent 30 day share price return of 16.5% contrasts with a 62.6% total shareholder return over the past year. This suggests that earlier gains have...
SWX:NESN
SWX:NESNFood

Nestlé Waters Stake Sale Advances As Valuation Gap Draws Investor Attention

Nestlé is advancing the sale of its stake in its waters business, with private equity bidders moving forward in the process. The potential transaction is part of a broader effort to reshape the portfolio toward core areas such as coffee, pet food, nutrition, and food. The outcome of the bidding could influence how Nestlé allocates capital and manages its mix of brands in the coming years. For investors following SWX:NESN, this potential sale comes as the share price stands at CHF76.37, with...
SWX:MOVE
SWX:MOVEMedical Equipment

Assessing Medacta Group (SWX:MOVE) Valuation After Dividend Increase And Double Digit Growth Targets

Dividend and guidance draw attention to Medacta Group Medacta Group (SWX:MOVE) has attracted fresh investor interest after announcing an annual dividend of CHF 1.10 per share and issuing 2026 revenue growth guidance in a 10% to 14% range in constant currency. See our latest analysis for Medacta Group. The stock’s 1-day share price return of 1.62% contrasts with a weaker year-to-date share price return showing a 5.05% decline, while the 1-year total shareholder return of 14.85% points to...
SWX:LOGN
SWX:LOGNTech

Does Logitech’s New US$1.40 Billion Buyback and Racing Gear Launch Shift the Bull Case for (SWX:LOGN)?

In March 2026, Logitech International announced a new three-year share repurchase program of up to US$1.40 billion, alongside leadership changes and, on March 17, the global launch of the Logitech G RS H‑Shifter for sim racing enthusiasts. Together, the sizeable buyback authorization and expansion of Logitech’s high-end racing ecosystem highlight management’s focus on capital return and deepening engagement with committed gaming users. We’ll now examine how the US$1.40 billion share...
SWX:VAHN
SWX:VAHNInsurance

European Dividend Stocks To Consider Now

As European markets navigate heightened geopolitical tensions and soaring energy costs, investors are increasingly focused on the potential impact of these factors on inflation and economic stability. In this uncertain environment, dividend stocks may offer a measure of resilience by providing regular income streams that can help cushion against market volatility.
SWX:STMN
SWX:STMNMedical Equipment

European Growth Companies Backed By Insider Confidence

As European markets navigate the challenges of heightened energy prices and geopolitical tensions, investors are increasingly focused on companies that demonstrate resilience and potential for growth. In such uncertain times, stocks with high insider ownership can signal strong confidence from those who know the business best, making them attractive candidates for consideration in a volatile market environment.